| pubmed-article:3165971 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:3165971 | lifeskim:mentions | umls-concept:C0008976 | lld:lifeskim |
| pubmed-article:3165971 | lifeskim:mentions | umls-concept:C1456575 | lld:lifeskim |
| pubmed-article:3165971 | lifeskim:mentions | umls-concept:C0205390 | lld:lifeskim |
| pubmed-article:3165971 | lifeskim:mentions | umls-concept:C0050560 | lld:lifeskim |
| pubmed-article:3165971 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:3165971 | pubmed:dateCreated | 1988-9-27 | lld:pubmed |
| pubmed-article:3165971 | pubmed:abstractText | Six patients with relapsed or refractory acute leukemia were treated with 9 mg/m2 or 11 mg/m2 of acivicin daily for seven days in a phase I-II trial. No responses were attained and further dose escalation was prohibited by neurotoxicity in 2 of 3 patients who received 11 mg/m2/day. Although acivicin appears to have limited potential as a single agent, laboratory evaluation of leukemic blasts in one patient revealed cell cycle (S-phase accumulation) and metabolic effects which suggest that acivicin may be effective as a modulator of other antileukemia agents such as cytosine arabinoside. | lld:pubmed |
| pubmed-article:3165971 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3165971 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3165971 | pubmed:language | eng | lld:pubmed |
| pubmed-article:3165971 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3165971 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:3165971 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3165971 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3165971 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3165971 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3165971 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:3165971 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:3165971 | pubmed:issn | 0167-6997 | lld:pubmed |
| pubmed-article:3165971 | pubmed:author | pubmed-author:PowellB LBL | lld:pubmed |
| pubmed-article:3165971 | pubmed:author | pubmed-author:CapizziR LRL | lld:pubmed |
| pubmed-article:3165971 | pubmed:author | pubmed-author:RichardsFF2nd | lld:pubmed |
| pubmed-article:3165971 | pubmed:author | pubmed-author:CraigJ BJB | lld:pubmed |
| pubmed-article:3165971 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:3165971 | pubmed:volume | 6 | lld:pubmed |
| pubmed-article:3165971 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:3165971 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:3165971 | pubmed:pagination | 41-4 | lld:pubmed |
| pubmed-article:3165971 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:3165971 | pubmed:meshHeading | pubmed-meshheading:3165971-... | lld:pubmed |
| pubmed-article:3165971 | pubmed:meshHeading | pubmed-meshheading:3165971-... | lld:pubmed |
| pubmed-article:3165971 | pubmed:meshHeading | pubmed-meshheading:3165971-... | lld:pubmed |
| pubmed-article:3165971 | pubmed:meshHeading | pubmed-meshheading:3165971-... | lld:pubmed |
| pubmed-article:3165971 | pubmed:meshHeading | pubmed-meshheading:3165971-... | lld:pubmed |
| pubmed-article:3165971 | pubmed:meshHeading | pubmed-meshheading:3165971-... | lld:pubmed |
| pubmed-article:3165971 | pubmed:meshHeading | pubmed-meshheading:3165971-... | lld:pubmed |
| pubmed-article:3165971 | pubmed:meshHeading | pubmed-meshheading:3165971-... | lld:pubmed |
| pubmed-article:3165971 | pubmed:meshHeading | pubmed-meshheading:3165971-... | lld:pubmed |
| pubmed-article:3165971 | pubmed:year | 1988 | lld:pubmed |
| pubmed-article:3165971 | pubmed:articleTitle | Phase I-II trial of acivicin in adult acute leukemia. | lld:pubmed |
| pubmed-article:3165971 | pubmed:affiliation | Oncology Research Center, Bowman Gray School of Medicine of Wake Forest University, Winston-Salem, North Carolina. | lld:pubmed |
| pubmed-article:3165971 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:3165971 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
